sa-mRNA Flu Shot Candidates Preps for Clinical Studies

Massachusetts-based CSL Seqirus recently announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates.

The data indicates that the sa-mRNA influenza vaccine candidates produced a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1).

Unlike standard mRNA vaccines, sa-mRNA instructs the body to replicate mRNA, amplifying the amount of protein made.

This could enable vaccine manufacturers to potentially develop more effective vaccines with a smaller dosage and with lower rates of reactogenicity, underscoring the value in both pandemic and seasonal settings.

"These preclinical data show the potential of sa-mRNA technology to protect against pandemic and seasonal influenza in one vaccine dose," said Ethan Settembre, Ph.D., Vice President, Research, CSL R&D Seqirus Vaccines Innovation Unit and study author, in a press release on October 5, 2022.

"As we look toward initiating our Phase 1 clinical trials in the near future, these data are an encouraging testament to the value of pursuing innovative vaccine technology platforms like sa-mRNA."

These data were published in Molecular Therapy – Methods and Clinical Development (Oct. 3/22)

Influenza is a common, contagious respiratory disease that may cause severe illness and life-threatening complications in some people, says the U.S. CDC.

The CDC recommends annual vaccination for individuals aged six months and older who do not have any contraindications get vaccinated by the end of October 2022.

Various influenza vaccines are available at clinics and local pharmacies in the USA.

Additional flu shot news for 2022 is posted at PrecisionVaccinations.com/Flu.